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Fibromyalgia is a chronic idiopathic pain syndrome characterized by widespread 
musculoskeletal pain and a deep range of other symptoms including disordered 
sleep, paresthesia, depression and anxiety (1). To date, its aetiopathogenesis and 
pathophysiology are still not understood, but the musculoskeletal, neuroendocrine 
and central nervous systems appear to play major roles in the development and pro-
gression of fibromyalgia (2). Important factors involved in the pathogenic process 
of fibromyalgia are oxidative stress and inflammation suggesting that antioxidative 
supplementation might be important in the management and modulation of fibro-
myalgia. Recent evidences suggest that melatonin may be suitable for this purpose. 
Melatonin is a small, highly conserved pineal indoleamine and due to its important 
and well known antioxidant and antinflammatory properties, together with also its 
analgesic effects, our research group studied the beneficial effects of the melatonin 
oral supplementation against the pathogenetic process of fibromyalgia. In detail, 
Sprague Dawley rats were randomly treated with reserpine, to reproduce the patho-
genic process of fibromyalgia (3), and/or with melatonin (MelapureTM by Flamma 
S.p.A.). At the end of the treatments, the animals treated with reserpine showed mod-
erate alteration at hind limb skeletal muscle level with difficult in moving, together 
with a significant expression of several oxidative stress and inflammatory markers 
at the gastrocnemius muscle level. Interestingly, melatonin, dose and time depend-
ently, reduced the difficulties in walking and the musculoskeletal oxidative stress and 
inflammatory processes. In summary, this pilot study suggested that melatonin could 
be an in vivo effective tool against muscoloskeletal morphofunctional damages and 
dysfunctions in the management of fibromyalgia-related complications.
Sincere thanks to Flamma S.p.A.- Italy (www.flammagroup.com) for courteously 
providing the melatonin and for the precious economic support to this study.
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